Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease in the European Journal of Endocrinology
Long-term findings from the multicentre, international LINC 3 study demonstrated that treatment with Isturisa® (osilodrostat) maintains cortisol normalisation and is well tolerated in most patients with Cushing’s disease. PUTEAUX, France–(BUSINESS WIRE)–Recordati Rare Diseases announce today publication of the long-term outcomes from the open-label extension period of the Phase III LINC 3 study of Isturisa® in … [Read more…]
